Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma has entered a definitive merger agreement to acquire InnocsAI, a biotechnology company focused on advanced CAR-T and antibody-based oncology therapies. The transaction values InnocsAI at approximately $320 million, with existing members receiving 1.6 billion shares of Liminatus common stock at $0.20 per share, plus contingent value rights for 20% of future net proceeds from strategic transactions.
Key figures
- Deal Value Usd
- 320000000
- Offering Price
- 0.2
- Shares Offered
- 1600000000
- Cvr percentage
- 20%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.